A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04078386 |
|
Recruitment Status :
Completed
First Posted : September 6, 2019
Last Update Posted : January 11, 2022
|
Sponsor:
RemeGen Co., Ltd.
Information provided by (Responsible Party):
RemeGen Co., Ltd.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | June 23, 2021 |
| Actual Study Completion Date : | October 26, 2021 |